Depressive DisordersAlcohol Use Disorder (AUD)Tobacco/Nicotine Use Disorder (TUD)Substance Use Disorders (SUD)Psilocybin

Psilocybin for treating substance use disorders?

This study (2017) reviews the human evidence regarding psilocybin as a potential treatment for substance use disorders (SUD). The authors conclude that the evidence thus far seems promising, but will need to be confirmed in future studies.

Authors

  • Arnt Schellekens

Published

Expert Review of Neurotherapeutics
meta Study

Abstract

Introduction: Evidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and cognitive and emotional processes mediating psilocybin’s effects. Psilocybin’s chemical structure is similar to that of serotonin. Dysregulations in the serotonin system are associated with alterations in stress hormones, such as cortisol, and mood disorders. After psilocybin administration cortisol levels spike and activate the executive control network, with subsequent increased control over emotional processes, and relief of negative thinking and persistent negative emotions. Preliminary data of ongoing alcohol and smoking addiction studies in humans shows promising effects of psilocybin administration on substance use. Importantly, psilocybin has a low risk of toxicity and dependence and can be used safely under controlled clinical conditions.Areas covered: This paper is a narrative review based on the search terms: psilocybin, substance use disorder, addiction, depression, serotonin. Literature on potential efficacy and mechanisms of action of psilocybin in SUD is discussed.Expert commentary: Recent positive findings with psilocybin need confirmation in well-designed placebo controlled randomized trials employing a large sample size.

Available with Blossom Pro

Research Summary of 'Psilocybin for treating substance use disorders?'

Introduction

De Veen and colleagues frame substance use disorders (SUDs) as prevalent, chronic conditions with high relapse rates despite existing psychological and pharmacological treatments. The introduction emphasises that roughly 50-60% of patients with drug and alcohol use disorders relapse within 6–12 months after treatment and argues that novel interventions that reduce craving and substance use are urgently needed. The authors point to hallucinogens, in particular psilocybin, as a candidate treatment given recent promising findings and its pharmacological actions on serotonin systems implicated in emotion, stress and cognitive control. This narrative review aims to summarise human and relevant preclinical evidence for psilocybin’s therapeutic potential in SUD, and to discuss putative mechanisms of action through receptor systems, brain regions and cognitive and emotional processes. The authors set out to integrate clinical observations (including pilot studies in alcohol and tobacco dependence), neuropharmacology, neuroanatomy and network-level effects to generate hypotheses about how psilocybin might reduce addictive behaviour and inform directions for future research.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (17)

Papers cited by this study that are also in Blossom

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)

89 cited
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Show all 17 references
The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)

Cited By (12)

Papers in Blossom that reference this study

An open-label pilot study of psilocybin-assisted therapy for binge eating disorder

Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)

Classic psychedelics do not affect T cell and monocyte immune responses

Rudin, D., Areesanan, A., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)

Traditional Amazonian medicine in addiction treatment: Qualitative results

O'shaughnessy, D. M., Sarnyai, Z., Quirk, F. et al. · SSM Qualitative Research in Health (2022)

Psychedelic Cognition-The Unreached Frontier of Psychedelic Science

Balaet, M. · Frontiers in Neuroscience (2022)

Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil

Maia, L. O., Massarentti, C. M., Tófoli, L.F. · Psychopharmacology (2022)

28 cited
Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis

Yang, F., Yang, S., Tseng, P. et al. · Psychiatry Investigation (2021)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Show all 12 papers

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.